stoxline Quote Chart Rank Option Currency Glossary
Aileron Therapeutics, Inc. (ALRN)
3.21  -0.01 (-0.31%)    06-17 16:00
Open: 3.34
High: 3.34
Volume: 36,009
Pre. Close: 3.22
Low: 3.2
Market Cap: 69(M)
Technical analysis
2024-06-17 5:21:24 PM
Short term     
Mid term     
Targets 6-month :  4.23 1-year :  4.67
Resists First :  3.62 Second :  4
Pivot price 3.24
Supports First :  3.01 Second :  2.51
MAs MA(5) :  3.23 MA(20) :  3.34
MA(100) :  4.65 MA(250) :  3.08
MACD MACD :  -0.3 Signal :  -0.3
%K %D K(14,3) :  29.6 D(3) :  28.8
RSI RSI(14): 33.6
52-week High :  7.42 Low :  1
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ALRN ] has closed above bottom band by 37.8%. Bollinger Bands are 82.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.35 - 3.37 3.37 - 3.38
Low: 3.15 - 3.18 3.18 - 3.2
Close: 3.18 - 3.21 3.21 - 3.24
Company Description

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.

Headline News

Mon, 17 Jun 2024
Aileron Therapeutics, Inc. (NASDAQ:ALRN) Sees Significant Decrease in Short Interest - Defense World

Sat, 15 Jun 2024
Of Texas/Texas Am I. University Sells 9342 Shares of Aileron Therapeutics, Inc. (NASDAQ:ALRN) Stock - Defense World

Fri, 14 Jun 2024
Of Texas/Texas Am I. University Sells 9577 Shares of Aileron Therapeutics, Inc. (NASDAQ:ALRN) Stock - Defense World

Wed, 12 Jun 2024
Of Texas/Texas Am I. University Sells 9,342 Shares of Aileron Therapeutics, Inc. (NASDAQ:ALRN) Stock - MarketBeat

Fri, 07 Jun 2024
Insider Selling: Aileron Therapeutics, Inc. (NASDAQ:ALRN) Major Shareholder Sells 6,291 Shares of Stock - MarketBeat

Thu, 16 May 2024
Aileron Therapeutics Announces New Interim CFO Appointment - - TipRanks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 22 (M)
Shares Float 20 (M)
Held by Insiders 0.6 (%)
Held by Institutions 23.4 (%)
Shares Short 257 (K)
Shares Short P.Month 43 (K)
Stock Financials
EPS -3.24
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.66
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -20 %
Return on Equity (ttm) -34.3 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.86
Qtrly Earnings Growth 0 %
Operating Cash Flow -20 (M)
Levered Free Cash Flow -9 (M)
Stock Valuations
PE Ratio -1
PEG Ratio -2.6
Price to Book value 1.2
Price to Sales 0
Price to Cash Flow -3.4
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android